ARCHIVES

AZURE Trial: Zoledronic Acid Didn’t Improve DFS In Stage II/III

This article is from The Cancer Letter archive.

Vol. 33 No. 12 | December 31, 2010

Download PDF Visit The Full Archive

Related Articles

Tacoma Hospital Finds Cancer DRGs Are Profitable

February 17, 1984

NCI, NINCDS Need Patients For Brain, Breast Studies

September 10, 1982

TCGA Researchers Discover Stomach Cancer Falls Into Four Distinct Molecular Subtypes

August 29, 2014

After Year-Long Review, Varmus Removes “Reasonable Pricing” Clause From CRADA

April 14, 1995

Cancer Rates May Rise 50% By 2020, IARC Says

April 18, 2003

Will Insurers Pay Patient Care Costs? Stay Tuned For Act II Of This Oncodrama

July 31, 1998